Skip to main content
Figure 2 | Nutrition Journal

Figure 2

From: Clinical and biochemical effects of a combination botanical product (ClearGuard™) for allergy: a pilot randomized double-blind placebo-controlled trial

Figure 2

Nasal Symptom Scale scores by time and treatment. Results from an 8-hour period of at-home ratings by subjects following the laboratory-based Nasal Allergen Challenge. Because not all subjects underwent the full dose-response in the laboratory, the results above represent symptoms following a maximum dose of 250, 1250, or 6250 AU/ml from, respectively, 5, 2, and 13 subjects in the Placebo treatment condition; 6, 1, and 13 subjects in the loratadine treatment condition; and 4, 2, and 13 subjects in the CBP treatment condition.

Back to article page

Nutrition Journal

ISSN: 1475-2891

Contact us